至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy

Clinical & Translational Immunology. 2017; 
Thi HO Nguyen Amabel CL Tan, Sue D Xiang, Anne Goubier, Kim L Harland, E Bridie Clemens, Magdalena Plebanski and Katherine Kedzierska
Products/Services Used Details Operation
Peptide Synthesis BMLF1280-288-GLCTLVAML (EBV), GAG77-85-SLYNTVATL (HIV), Survivin95-104 (ELTLGEFLKL) (SV3), Survivin96-104-LTLGEFLKL (SV4), Survivin96-104 variant-LMLGEFLKL (SV10) and WT1126-134-RMFPNAPYL (WT1A) peptides were synthesized by Mimitopes (Notting Hill, VIC, Australia). WT1A was also synthesized by CS Bio (Menlo Park, CA, USA). WT1126-134 variant-YMFPNAPYL (WT1B) and HPV-E786-93-TLGIVCPI (HPV-E7) was from Auspep (Tullamarine, VIC, Australia) and influenza A M158-66-GILGFVFTL was from Genscript Get A Quote

摘要

The Wilms’ tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1126-134 (RMFPNAPYL) (HLA-A2/RMFPNAPYL epitope (WT1A)) and its modified variant YMFPNAPYL (HLA-A2/YMFPNAPYL epitope (WT1B)), can induce WT1-specific CD8+ T cells, although WT1B is more stably bound to HLA-A*02:01. Here, to further determine the benefits of those two targets, we assessed the naive precursor frequencies; immunogenicity and cross-reactivity of CD8+ T cells directed toward these two WT1 epitopes. Ex vivo naive WT1A- and WT1B-specific CD8+ T cells were detected in healthy HLA-A*02:01... More

关键词